Hospitalized patients with community-acquired pneumonia who received treatment regimens against atyical disease-causing pathogens reached clinical stability quicker, had fewer days of hospitalization and had lower mortality rates as a result of their disease, according to a large new study.
May 18, 2007 marks the 10th annual HIV Vaccine Awareness Day, an opportunity to reflect upon the more than two decades of progress worldwide in the search for a safe and effective HIV vaccine.
Boehringer Ingelheim GmbH announced that it has initiated and begun enrollment of patients in the ArTEN trial, which will compare the efficacy and safety of Viramune? (nevirapine), a non-nucleoside reverse transcriptase inhibitor (NNRTI), dosed once daily (QD) or twice daily (BID), versus atazanavir/ritonavir, a once-daily dosed protease inhibitor (PI).
The antiviral drug peramivir might offer humans significant protection during a pandemic of the avian influenza virus H5N1, according to results of mouse studies conducted by investigators at St. Jude Children’s Research Hospital.
People with HIV who drop out of care do not live as long as those who remain under a doctor’s treatment, said Baylor College of Medicine and Veterans Affairs researchers in a report published in the June 1 issue of Clinical Infectious Diseases and available on line.
UCLA AIDS Institute researchers have discovered that when a crucial portion of a peptide structure in monkeys that defends against viruses, bacteria and other foreign invaders is reversed, the peptide actually encourages infection with HIV.
The U.S. Food and Drug Administration (FDA) cleared for marketing the first respirators that can help reduce the user’s exposure to airborne germs during a public health medical emergency, such as an influenza pandemic.
More than 500 scientists, clinicians and public health specialists met today at the National Institutes of Health (NIH) to discuss the latest research on drug abuse and the evolving epidemic of HIV/AIDS. This is the first-ever two-day public meeting at NIH to include a focus on non-injection drug use and HIV transmission.
U.S. and Indian health officials have renewed the Indo-U.S. Vaccine Action Program (VAP), a 20-year-old bilateral collaboration supporting research on vaccines, immunology and related biomedical issues. The VAP aims to reduce the burden of vaccine-preventable diseases of public health significance in India, the United States and other parts of the world, and to promote vaccines as one of the most cost-effective health technologies.
Respiratory syncytial virus (RSV) infection is a widespread infant illness that has been linked to asthma and can be deadly but may be curable by the development of this new vaccine technology by the Sir Albert Sakzewski Virus Research Centre and The University of Queensland’s Faculty of Biological and Chemical Sciences.